In a second step, we aimed to evaluate BC intra-tumor heterogeneity using the DEPArrayTM-HER2-FISH workflow in another 25 BC patients (development cohort) characterized as HER2-neg (DAKO-Score 0 or + 1) on the PT but HER2/neu-pos on CTCs. This evidence concerns the gene ERBB2 and breast cancer.